Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?

Upendra P Hegde; Bijay Mukherji; Jane M Grant-Kels

doi:10.2217/mmt.15.39

Emerging immune therapy of metastatic melanoma in the older patient: does age really matter?

Melanoma Manag. 2016 Mar;3(1):9-12. doi: 10.2217/mmt.15.39. Epub 2016 Feb 17.

Authors

Upendra P Hegde^{1

2

1

2}, Bijay Mukherji^{1

1}, Jane M Grant-Kels^{1

1}

Affiliations

¹ University of CT Health Center Cutaneous Oncology & Melanoma Center, 21 South Road, Farmington, CT 06030, USA.
² Neag Cancer Center at UCONN Health, Farmington, CT 06032, USA.

No abstract available

Keywords: T cells; aging; anti-CTLA-4; anti-PD-1; effector T cells; elderly; immune checkpoint inhibitor; immunosenescence; immunotherapy; metastatic melanoma; regulatory T cells.

Publication types

Editorial